LivaNova permitted to modify cardiopulmonary products’ indications for use to include ECMO therapy to address COVID-19
On Apr. 22, 2020, LivaNova announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for Extracorporeal Membrane Oxygenation (ECMO) therapy greater than six hours per guidance issued by the U.S. Food and Drug Administration (FDA) on Apr. 6 to temporarily expand the availability of devices to address the coronavirus (COVID-19) pandemic.
Tags:
Source: LivaNova
Credit:
